Public Release: 

Less intensive chemo avoids irreversible side effects in children's cancer

Cancer Research UK

CHILDREN with a rare type of cancer called Wilms' tumour who are at low risk of relapsing can now be given less intensive treatment, avoiding a type of chemotherapy that can cause irreversible heart problems in later life.

The move follows the results of a Cancer Research UK trial, published in the Lancet* today (Thursday), showing that the drug doxorubicin can be safely omitted from treatment without affecting patients' chances of survival.

Wilms' tumour is a type of kidney cancer that affects around 80 children a year in the UK, most under the age of seven. Until now, about one half of these patients would have received doxorubicin as part of their treatment, which carries a small but significant risk of heart problems in later life**. Now only about one quarter of children - those at the greatest risk of relapse - need the drug.

Doxorubicin is helpful in treating many types of cancer. But with around nine in 10 children with Wilms tumour now cured, doctors wanted to find out whether it could be safely left out from the treatment of those who had a low chance of relapse, without affecting survival chances.

583 children with stage II or stage III Wilms' tumour, who were at intermediate risk of relapsing, took part in the 10 year trial from 2001-2011 across 26 European countries***.

The results showed that 96.5 per cent of children whose treatment included doxorubicin survived for five years or more, compared with 95.8 per cent of children who didn't receive the drug. Although there were slightly more relapses among the children who avoided doxorubicin, they could all be successfully re-treated, meaning there was no impact on the overall risk of death.

The researchers are now carrying out further work, funded by Cancer Research UK, to pinpoint genetic changes in tumour samples from these patients that could be used to better predict the chance of relapse, so treatment can be tailored accordingly.

Lead author Professor Kathy Pritchard-Jones, a Cancer Research UK-funded researcher at the Institute of Child Health, University College London and consultant oncologist at Great Ormond Street Hospital in London, said: "Thanks to the results of this trial fewer children with this disease will have to have treatment that could cause them lifelong side effects without much benefit. It's taken researchers in 26 countries nearly 10 years to gather the data to support this theory, and none of this would have been possible without the 583 children who took part in the trial and the families that supported them."

Professor Pam Kearns, professor of paediatric oncology at the University of Birmingham and Cancer Research UK's senior clinical advisor, said: "This is a very important trial that has changed clinical practice for this type of Wilms' tumour. Around nine in 10 children with the disease survive with current treatments, so it is difficult to consider reducing treatment, but minimising the side effects that occur later in life is crucial. Thanks to trials like this we're learning how we can both improve treatments for children's cancers alongside reducing the damaging side effects.

"Whilst treatment for Wilms' tumour is very successful, overall cancer remains the biggest killer of children in the UK so our work is still far from done. Our new campaign - Cancer Research UK Kids & Teens - will help us fund more research to find cures and kinder treatments to beat children's cancer in the future."

###

Notes to editor

* Pritchard-Jones K. et al. Doxorubicin omission from the treatment of stage II-III, intermediate-risk histology Wilms' tumour: results of the SIOP WT 2001 randomised trial, Lancet (2015), DOI: 10.1016/S0140-6736

** About 1 in 20 children treated with doxorubicin experience heart problems in early adulthood. The risk of heart problems in older adults is not yet known.

*** The standard treatment is surgery and chemotherapy, with radiotherapy given to stage III tumours. After the operation to remove their kidney tumour, when the tumour stage is known, children were randomly assigned to receive their chemotherapy either with or without doxorubicin.

For more information about the trial visit: http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-treatment-for-children-and-young-people-with-kidney-cancer-including-wilms-tumour

For more information about Cancer Research UK Kids & Teens visit: http://www.cancerresearchuk.org/kidsandteens

About Cancer Research UK

  • Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
  • Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
  • Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
  • Cancer Research UK has been at the heart of the progress that has already seen survival rates in the UK double in the last forty years.
  • Today, 2 in 4 people survive cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that 3 in 4 people will survive cancer within the next 20 years.
  • Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
  • Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.

For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit http://www.cancerresearchuk.org. Follow us on Twitter and Facebook.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.